Pediatric Infectious Disease

Register      Login

VOLUME 1 , ISSUE 2 ( April-June, 2019 ) > List of Articles

REVIEW ARTICLE

Postexposure Prophylaxis in HIV in India: A Review

Keywords : Antiretroviral therapy, Exposure code, Healthcare personnel, HIV, Postexposure prophylaxis, Source code, Tenofovir disoproxil fumarate

Citation Information : Postexposure Prophylaxis in HIV in India: A Review. Pediatr Inf Dis 2019; 1 (2):52-57.

DOI: 10.5005/jp-journals-10081-1209

License: CC BY-NC 4.0

Published Online: 01-06-2019

Copyright Statement:  Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

The risk of exposure to HIV is high among certain populations like healthcare personnel (HCP), injection drug users (IDUs) and people engaged in unprotected sex. The timely reporting of the needle stick injury or potential exposure to HIV depends on the knowledge and understanding of PEP by the HCP. There is a delay in development of systemic infection after the initial exposure caused by the HIV replication in the dendritic cells of the skin and mucosa before spread through the lymphatic vessels. This window of opportunity can be utilized to block the replication of HIV by providing PEP. The case control study has demonstrated the reduction in acquisition of HIV by 81% after introduction of PEP among HCPs. Hence a comprehensive review on PEP among HCP, particularly with reference to Indian context is presented here.


PDF Share
  1. National Technical guidelines on Antiretroviral Treatment. National AIDS Control Organisation: Ministry of Health and Family Welfare Government of India. Oct 2018.
  2. Kaplan JE, Dominguez K, Jobarteh K, et al. Postexposure prophylaxis against human immunodeficiency virus (HIV): new guidelines from the WHO: a perspective. CID 2015;60(S3):S196–S199.
  3. Sultan B, Benn P, Waters L. Current perspective in HIV post-exposure prophylaxis. HIV AIDS 2014;6:147–158. DOI: 10.2147/HIV.S46585.
  4. Siegfried N, Beanland RL, Ford N, et al. Formulating the future research agenda for postexposure prophylaxis for HIV: methodological challenges and potential approaches. CID 2015;60(S3):S205–S211. DOI: 10.1093/cid/civ139.
  5. Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review. CID 2015;60(S3):S170–S176. DOI: 10.1093/cid/civ092.
  6. Penazzato M, Dominguez K, Cotton M, et al. Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review. CID 2015;60(S3):S177–S181.
  7. Ford N, Mayer KH. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. CID 2015;60(S3):S161–S164. DOI: 10.1093/cid/civ068.
  8. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2016: recommendations for a Public Health Approach second edition. WHO 2016.
  9. http://www.upsacs.in/pdf/GUIDELINES/PEP.pdf.
  10. Wyżgowski P, Rosiek A, Grzela T, et al. Occupational HIV risk for health care workers: risk factor and the risk of infection in the course of professional activities. Ther Clin Risk Manag 2016;12:989–994. DOI: 10.2147/TCRM.S104942.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.